News Focus
News Focus

12x

Followers 17
Posts 523
Boards Moderated 0
Alias Born 08/04/2022

12x

Re: Investor2014 post# 475786

Monday, 12/02/2024 8:53:50 AM

Monday, December 02, 2024 8:53:50 AM

Post# of 517475
The COL24A1 is also linked to PD per ChatGPT so the genetic clusters poster might have missed it. It would be nice to re-run the study with AD data.

What do you think of the "Significant Benefits" mean? It's interesting that typical wording like "significantly slowing" is not used. The "significantly" must be based on p-value but there is no placebo control group. Compared to ADNI? Even Leqembi did not calculate StatSig against ADNI.

PHASE IIB/III ATTENTION-AD STUDY: OVER THREE YEARS OF CONTINUOUS TREATMENT WITH ORAL BLARCAMESINE CONTINUES TO SIGNIFICANTLY BENEFITS EARLY ALZHEIMER'S DISEASE PATIENTS

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News